Cuorips, Inc. (hereinafter “Cuorips”, Head office: Chuo-ku Tokyo, President & CEO：Naoko Iino) hereby announced that about 1 billion yen was raised through third-party allocation of new shares from Daiichi Sankyo, Co. Ltd. (Head office：Chuo-ku Tokyo), Kyoto University Innovation Capital Co. Ltd. (Head Office：Sakyo-ku, Kyoto) and Terumo Co. Ltd.（Head Office：Shibuya-ku Tokyo）etc..
【Background and Purpose of third-party allocation of new shares】
After established in March 2017, Cuorips has started research activities at Frontier of Regenerative Medicine Joint Research Chair (hereinafter Joint Research Chair) in Osaka University, and then entered research and development collaboration agreement with Daiichi Sankyo Co. Ltd. in Oct 2017.
Cuorips opened new research facility in Suita Campus of Osaka University. At this new facility and the Joint Research Chair in February 2018, and has been working on research on manufacturing process of iPS-derived cardiomyocyte sheets that would be used in Osaka University’s Investigator Initiated Study. Cuorips is also working on the establishment of manufacturing system for clinical supply, and the ground plan on manufacturing facility.
Under this circumstance, Cuorips has decided to get additional funds that is need for further timeline acceleration of the research and development.
Cuorips will continue to work in collaboration with researchers at Osaka University, aiming to deliver innovative medicine for heart failure.
＜Inquiries related to this press release＞
Cuorips, Inc. Business Planning Office
Mail : email@example.com
507 Nihonbashi Life Science Building2,
3-11-5, Nihonbashi-honcho, Chuo-ku,Tokyo